Loading
NASDAQHealthcareBiotechnology
Latest quote
$16.1266
−$0.7634 · -4.52%
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Regular session
$16.1266
−$0.7634 · -4.52%
Regular session · ET · Market data may be delayed.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Day range
Current $16.1266
52-week range
Current $16.1266
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
36
Expensive
Sentiment
58
Mixed
Risk
46
Elevated Risk
Momentum
67
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Day range
Current $16.1266
52-week range
Current $16.1266
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI40.23M0.00%2.3T USD0.03%$379.54-0.39%
iShares Russell 2000 ETFIWM16.8M0.02%78.56B USD0.19%$274.77-1.06%
State Street SPDR S&P Biotech ETFXBI14.52M0.14%10.08B USD0.35%$146.57-2.44%
Vanguard Extended Market ETFVXF12.07M0.01%95.4B USD0.05%$231.31-0.93%
Vanguard Russell 2000 ETFVTWO6.54M0.04%18B USD0.06%$110.97-1.11%
iShares Russell 2000 Growth ETFIWO5.96M0.04%14.25B USD0.24%$350.48-1.38%
iShares Biotechnology ETFIBB4.43M0.04%10.4B USD0.44%$197.41-2.92%
Schwab U.S. Small-Cap ETFSCHA3.27M0.02%21.7B USD0.03%$32.295-0.97%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
